LC-MS/MS Assay Standardizes IGF-1 Measurement for Endocrine Health

Insulin-like Growth Factor 1 (IGF-1) is a crucial hormone involved in growth, metabolism, and cell proliferation, making its accurate measurement vital for diagnosing and monitoring various endocrine disorders. Conditions such as growth hormone deficiency, acromegaly (excess growth hormone), and Laron syndrome rely heavily on precise IGF-1 levels for diagnosis. However, current immunoassay methods often suffer from significant variability, matrix interferences, and lack of standardization, leading to diagnostic challenges and potential misinterpretations. This study addresses the critical need for a highly accurate, precise, and standardized method for IGF-1 quantification in routine clinical practice.

The new LC-MS/MS assay demonstrated superior analytical performance, achieving an impressive inter-assay coefficient of variation of less than 5% and an intra-assay variation of <3%, indicating high precision and reproducibility. It exhibited excellent linearity across the physiological range (R² > 0.995) and minimal matrix effects, which are common issues with older methods. > The established normative dataset, derived from 2,000+ healthy individuals, revealed age- and sex-specific IGF-1 reference ranges that differed by up to 15% from previously used reference intervals based on conventional immunoassay methods. Furthermore, the LC-MS/MS assay showed a 98% concordance with a gold-standard reference method, significantly outperforming conventional immunoassays which exhibited up to 20% discrepancy in certain clinical samples, particularly those with interfering factors or extreme IGF-1 levels. This improved accuracy is crucial for distinguishing between healthy and pathological states.